StockNews.AI
MTVA
StockNews.AI
70 days

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

1. MTVA to present at Life Sciences Virtual Investor Forum on June 12, 2025. 2. Recent trials for DA-1241 and DA-1726 showed positive results. 3. Closed a $10 million private placement benefiting future developments. 4. DA-1726 demonstrated significant weight loss in clinical trials. 5. Live Q&A session allows investor interaction post-presentation.

8m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial results for DA-1241 and DA-1726 could increase investor confidence, similar to past biotech surges after successful trial announcements.

How important is it?

The announcement and clinical trial outcomes are directly relevant to investor perceptions, potentially driving share price changes.

Why Short Term?

Upcoming presentation and recent trial successes could lead to immediate positive market reactions from investors, creating short-term interest.

Related Companies

NVAXMRNAPFE
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com June 10, 2025 08:31 ET  | Source: Virtual Investor Conferences CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer will present a company overview live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, taking place June 11-12, 2025. DATE: Wednesday June 12, 2025 TIME: 1:00 – 1:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12, 13, and 16 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.   Learn more about the event at www.virtualinvestorconferences.com. To schedule a meeting with management outside of this event, investors can contact Michael Miller at mmiller@rxir.com. Recent Company Highlights May 2025: Closed a private placement, which resulted in aggregate gross proceeds of $10 million priced at-the-market under Nasdaq rules.May 2025: Presented data from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed MASH in a late-breaking poster presentation at EASL Congress 2025. In this trial, DA-1241 significantly decreased plasma ALT levels, with a mean reduction of 22.8 U/L at 16 weeks, the Controlled Attenuation Parameter (CAP) Score improved by 23.0 dB/m, indicating reduced liver fat content, while an improvement in FibroScan-AST (FAST) score and NIS-4, supports beneficial effects on liver health.April 2025: Reported additional, positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity further demonstrating its best-in-class potential. DA-1726 demonstrated a clear dose-responsive trend in body weight reduction across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index, which shows body weight adjusted for height, showed a difference between the treatment group and the placebo group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. Of note, DA-1726 did not show any clinically significant increases in heart rate or QTcF changes up to 32 mg at 4 weeks of administration.April 2025: Announced positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity. DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity. The cohort receiving 32 mg of DA-1726 with no titration demonstrated a maximum reduction in body weight from baseline ranging up to -6.3%, and a mean body weight reduction of -4.3% at Day 26 (p=0.0005). Four out of six subjects on the 32 mg dose experienced mild gastrointestinal (GI) adverse events (AEs), most of which were resolved after 24 hours of occurrence. There were no treatment-related discontinuations or serious adverse events (SAEs). About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit www.metaviatx.com. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Contacts: MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033marshall.woodworth@metaviatx.com Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@otcmarkets.com 

Related News